Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.36 |
| ▸ | APOL1 | O14791 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15855802 | 1.00 | CCR2 (0.36) | CCR2APOL1TSHRPSEN1PSEN2 | |
| SCHEMBL5959020 | 0.92 | CCR2 (0.42) | CCR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7135998 | 0.90 | CCR2 (0.48) | CCR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21066906 | 0.90 | CCR2 (0.48) | CCR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7995776 | 0.90 | CCR2 (0.48) | CCR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2530439 | 0.76 | L3MBTL1 (0.36) | CCR2L3MBTL1 | |
| SCHEMBL5552436 | 0.74 | HSD11B1 (0.37) | L3MBTL1 | |
| SCHEMBL1198609 | 0.74 | HSD11B1 (0.37) | L3MBTL1 | |
| SCHEMBL1197732 | 0.74 | HSD11B1 (0.37) | L3MBTL1 | |
| SCHEMBL17032184 | 0.74 | CCR2 (0.33) | CCR2APOL1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| US-6297233-B1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | CCR2 2489/4885APOL1 873/4885TSHR 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.